- Trials with a EudraCT protocol (227)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
227 result(s) found for: Thyroid hormone.
Displaying page 4 of 12.
EudraCT Number: 2007-003910-33 | Sponsor Protocol Number: -- | Start Date*: 2007-11-19 | |||||||||||
Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS) | |||||||||||||
Full Title: Randomized controlled study of rituximab and steroid treatment in thyroid-associeted ophthalmopathy (TAO) | |||||||||||||
Medical condition: Thyroid associeted ophthalmopathy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000874-92 | Sponsor Protocol Number: LUM-201-01 | Start Date*: 2021-03-22 | |||||||||||
Sponsor Name:Lumos Pharma, Inc. | |||||||||||||
Full Title: A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficie... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005607-13 | Sponsor Protocol Number: NN8640-4467 | Start Date*: 2022-07-15 | ||||||||||||||||||||||||||
Sponsor Name:NOVO NORDISK. S.P.A. | ||||||||||||||||||||||||||||
Full Title: A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with ... | ||||||||||||||||||||||||||||
Medical condition: Short stature born small for gestational age Turner syndrome Noonan syndrome Idiopathic short stature | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) SI (Trial now transitioned) IE (Completed) DE (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017245-64 | Sponsor Protocol Number: OG09/9146 | Start Date*: 2010-09-07 |
Sponsor Name:Leeds Teaching Hospitals NHS Trust | ||
Full Title: The effect of metformin co-treatment in hormone-replacement frozen embryo replacement cycles in women with polycystic ovary syndrome. | ||
Medical condition: Polycystic Ovary Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-003874-42 | Sponsor Protocol Number: CP-4-006 | Start Date*: 2017-09-04 | |||||||||||
Sponsor Name:OPKO Biologics Ltd. | |||||||||||||
Full Title: A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiency | |||||||||||||
Medical condition: Growth hormone deficiency in pre-pubertal children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BG (Completed) FR (Completed) PL (Completed) ES (Ongoing) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004815-33 | Sponsor Protocol Number: TransCon_PTH_TCP-201 | Start Date*: 2019-09-27 | |||||||||||
Sponsor Name:Ascendis Pharma Bone Diseases A/S | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administ... | |||||||||||||
Medical condition: Hypoparathyroidism (HP) in Adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022534-84 | Sponsor Protocol Number: SP0978 | Start Date*: 2011-05-10 | |||||||||||
Sponsor Name:UCB Pharma SA | |||||||||||||
Full Title: A multi-center, open-label, single-arm study to evaluate hormone and lipid levels in male subjects with partial onset seizures after a switch of treatment from carbamazepine as adjunctive treatment... | |||||||||||||
Medical condition: Epilepsy: partial onset seizures. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001703-32 | Sponsor Protocol Number: CRN00808-08 | Start Date*: 2022-03-29 | |||||||||||
Sponsor Name:Crinetics Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) GR (Trial now transitioned) BG (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002260-31 | Sponsor Protocol Number: GINECO-OV243b | Start Date*: 2020-10-01 | |||||||||||||||||||||
Sponsor Name:ARCAGY-GINECO | |||||||||||||||||||||||
Full Title: Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line advanced small cell ovarian carcinoma of hypercalcemic type | |||||||||||||||||||||||
Medical condition: Advanced small cell ovarian carcinoma of hypercalcemic type | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003142-32 | Sponsor Protocol Number: TBR-760-NFPA-201 | Start Date*: 2020-07-16 | |||||||||||
Sponsor Name:Tiburio Therapeutics, Inc. | |||||||||||||
Full Title: A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients with Non-Functioning Pituitary Adenomas | |||||||||||||
Medical condition: Non-Functioning Pituitary Adenomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004495-36 | Sponsor Protocol Number: M90-516 | Start Date*: 2014-11-28 | |||||||||||
Sponsor Name:Abbvie previously known as Abbott | |||||||||||||
Full Title: Study of Lupron Depot in the Treatment of Central Precocious Puberty | |||||||||||||
Medical condition: Central Precocious Puberty | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004889-10 | Sponsor Protocol Number: DapaFIT | Start Date*: 2021-04-28 |
Sponsor Name:University Hospital Tuebingen | ||
Full Title: Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study | ||
Medical condition: Patients with T2DM and hypertension aged 40 to 70 years (including) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-010869-23 | Sponsor Protocol Number: THIRST 02/2009 | Start Date*: 2009-06-22 | ||||||||||||||||||||||||||
Sponsor Name:OSPEDALE G.PASQUINUCCI-FONDAZIONE TOSCANA GABRIELE MONASTERIO/CNR | ||||||||||||||||||||||||||||
Full Title: Acute and long term effects of thyroid hormone replacement therapy in patients with ST-Elevation Myocardial Infarction (STEMI) and borderline/reduced triiodothyronine levels. | ||||||||||||||||||||||||||||
Medical condition: All patients enrolled in the study should be in good clinical conditions, being ST-elevation myocardial infarction the main pathology,, without evidence of clinical/hemodynamic instability. All pat... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002379-40 | Sponsor Protocol Number: CAFQ056B2278 | Start Date*: 2012-01-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA GB (Prematurely Ended) ES (Temporarily Halted) DK (Prematurely Ended) IT (Completed) FR (Completed) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010787-42 | Sponsor Protocol Number: 2-55-52060-003 | Start Date*: 2009-09-02 | |||||||||||
Sponsor Name:Ipsen Pharma | |||||||||||||
Full Title: PHASE II, OPEN, RANDOMISED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS (S.C.) ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN ACR... | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) DE (Completed) FR (Completed) LT (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010952-81 | Sponsor Protocol Number: OG08/8802 | Start Date*: 2009-08-17 |
Sponsor Name:Leeds Teaching Hospitals NHS Trust | ||
Full Title: The use of Metformin and Gonadotrophin Releasing Hormone Antagonist for the treatment of women with Polycystic Ovary Syndrome undergoing In-vitro Fertilisation-Embryo Transfer. | ||
Medical condition: Polycystic ovary syndrome. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-001569-20 | Sponsor Protocol Number: 27709 | Start Date*: 2015-07-06 | |||||||||||
Sponsor Name:Merck Serono Co., Ltd. | |||||||||||||
Full Title: A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen® | |||||||||||||
Medical condition: Dwarfism, Pituitary | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002630-31 | Sponsor Protocol Number: CSOM230C2413 | Start Date*: 2015-03-25 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin ana... | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) PT (Completed) IT (Completed) FR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004413-33 | Sponsor Protocol Number: KBT-004 | Start Date*: 2007-10-26 | |||||||||||
Sponsor Name:Karo Bio AB | |||||||||||||
Full Title: A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB 2115 as add on to Statin Treatment in Patients With Dyslipid... | |||||||||||||
Medical condition: Primary hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001485-15 | Sponsor Protocol Number: MYR204 | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:Gilead Sciences Inc. | |||||||||||||
Full Title: A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta | |||||||||||||
Medical condition: Chronic Hepatitis Delta | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
